Invitrogen Inks Cancer Dx Pact with Signalomics; Welcomes Competition from Emerging Rivals | GenomeWeb

In the most recent in a series of efforts intended to push it further into molecular diagnostics, Invitrogen said this week that it would collaborate with German firm Signalomics to develop nanocrystal reagents for tumor identification.

The company also said it "welcomes" existing and impending competition from small, private shops because they will eventually become "collaboration" opportunities for Invitrogen.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.